Atara Biotherapeutics Seeks FDA Meeting to Address Tabelecleucel BLA Rejection

summarizeSummary

Atara Biotherapeutics announced that its partner has requested a Type A meeting with the FDA and submitted a briefing book to address issues raised in the Complete Response Letter for tabelecleucel's BLA.

check_boxKey Events

• FDA Type A Meeting Requested

  Atara's partner, Pierre Fabre Pharmaceuticals, has requested a Type A meeting with the FDA to discuss the plan to address issues raised in the Complete Response Letter for the EBVALLO™ Biologics License Application, issued on January 9, 2026.

• Briefing Book Submitted

  A briefing book was submitted to the FDA, providing additional context and clarification that the ALLELE study was adequate and sufficient to support the BLA, along with updated efficacy and post-marketing data from Europe.

auto_awesomeAnalysis

Atara Biotherapeutics is taking proactive steps to address the Complete Response Letter (CRL) issued by the FDA on January 9, 2026, for its Biologics License Application (BLA) for tabelecleucel (EBVALLO™). The request for a Type A meeting and the submission of a comprehensive briefing book demonstrate the company's commitment to finding a path forward for this critical product, which addresses a dire unmet medical need. This engagement with the FDA is an important step in the regulatory process and could potentially lead to a resubmission and eventual approval, which is crucial for a company of Atara's size.